Progenics completes enrollment in mCRPC trial

|About: Progenics Pharmaceuticals Inc. (PGNX)|By:, SA News Editor

Progenics Pharmaceuticals (PGNX +2.4%) completes enrollment in a Phase 2 study of PSMA ADC in metastatic castrate resistant prostate cancer.

The enrolled patients are chemotherapy experienced.

The company is also enrolling chemotherapy naive patients in a second cohort.

Top-line data from the chemotherapy experienced cohort is expected in January. (PR)